search  
 


Home

Who are we?

Why
register?


Signup for
registration


Online registration

Log in to register
your trial


Search a trial

NRT en CCMO

Contact

NEDERLANDS





MetaRegister
van CCT (UK)


ISRCTN-Register
van CCT (UK)


Screening op hersenmetastasen bij niet kleincellig longkanker: de psychologische impact van de diagnose asymptomatische hersenmetastasen; een focus groep onderzoek


- candidate number29360
- NTR NumberNTR7417
- ISRCTNISRCTN no longer applicable
- Date ISRCTN created
- date ISRCTN requested
- Date Registered NTR2-aug-2018
- Secondary IDsMETC 2017-0286 
- Public TitleScreening op hersenmetastasen bij niet kleincellig longkanker: de psychologische impact van de diagnose asymptomatische hersenmetastasen; een focus groep onderzoek
- Scientific TitleScreening for brain metastases in lung cancer: the psychological impact of being diagnosed with asymptomatic brain metastases, a qualitative study
- ACRONYM
- hypothesis
- Healt Condition(s) or Problem(s) studiedLung cancer, Non small cell lung cancer (NSCLC), Brain metastasis, Psychological impact
- Inclusion criteria- Stage IV lung cancer patients diagnosed with asymptomatic brain metastases detected by screening
- Stage IV lung cancer patients who were diagnosed in the past with asymptomatic brain metastases
- systemic treatment is allowed
or
- partners of stage IV lung cancer patient with asymptomatic brain metastases
- Exclusion criteria- Inability to interact in focus groups
- Other neurologic illness (such as Alzheimer's disease)
- mec approval receivedyes
- multicenter trialno
- randomisedno
- group[default]
- Type[default]
- Studytypeobservational
- planned startdate 1-mrt-2018
- planned closingdate1-jul-2019
- Target number of participants18
- InterventionsFocus group (no real intervention)
- Primary outcomeTo explore the psychological impact of being diagnosed with asymptomatic brain metastases for both the patients and their partners
- Secondary outcomeNot applicable
- Timepoints6 focusgroups within a year.
Analyzing 6 months.
Year after last focus group, publication.
- Trial web site
- statusopen: patient inclusion
- CONTACT FOR PUBLIC QUERIES L. Hendriks
- CONTACT for SCIENTIFIC QUERIES L. Hendriks
- Sponsor/Initiator Maastricht University Medical Center (MUMC+)
- Funding
(Source(s) of Monetary or Material Support)
Roche
- Publications
- Brief summary
- Main changes (audit trail)Approximately half of the patients with NSCLC already have metastasized disease (Stage IV) at diagnosis. About 25-40% of the lung cancer patients are diagnosed with brain metastases at initial stage IV diagnosis or will develop brain metastasis during the course of their disease. Since more and more molecular features are known in NSCLC with targetable drugs available the screening of patients with lung cancer for brain metastasis will become more and more mandatory as preventing symptomatic brain metastasis has important impact on quality of life. As brain metastases is associated with a poorer quality of life, knowing that there are asymptomatic brain metastases could therefore have an psychological impact on the quality of life, even when effective targeted treatment is available.

The aim of this study is to explore the psychological impact is of being diagnosed with asymptomatic brain metastasis for both the patients and their spouses.

Next we will investigate (depending on the results) whether there is a need for specific guidance or counseling at the outpatient clinic and develop new tools for improvement in the future.
- RECORD2-aug-2018 - 12-okt-2018


  • Indien u gegevens wilt toevoegen of veranderen, kunt u een mail sturen naar nederlands@trialregister.nl